Editor's note: The table in this Infographic was updated on March 5, 2019, to correct the development stage of Novartis's branaplam to Phase II, not Phase III as previously stated, and on March 8, 2019, to update the corresponding Likelihood of Approval score from 62% to 24%.
Scrip's Guide To Spinal Muscular Atrophy Therapies
Listen to this article
INFOGRAPHIC: The prospects for patients with spinal muscular atrophy, the leading cause of genetic death in infants, have been revolutionized by the arrival of the first approved drug for the disease, Biogen’s blockbuster Spinraza. Now, other firms with equally revolutionary product candidates are giving chase. Scrip takes a look at the main contenders.
Keep up with the top pharma business news of the week. On the go.
More from Rare Diseases
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
• By
Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.
• By
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
• By
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
